Omega-3 (EPA/DHA) for Depression
Long-chain polyunsaturated fatty acids from fish or algal oil that are incorporated into cell membranes and reduce pro-inflammatory eicosanoid production; linked to cardiovascular, joint, and neurological benefits.
Omega-3 (EPA/DHA) for Depression
3 of 10 results reported a benefit, from 2 published studies.
2 studies, including a review of trials · the chart counts everything measured
- 3 reported a benefit
- 7 no clear benefit
Colour keyReported a benefitNo clear benefitUnclearPossible harmAmber is for highlights, such as where the most research is. It never means a result was good.
- Depression remission rateNo clear difference13% higher odds1 review of trials2021 study ↗
- Depression symptomsMixed results2 reviews of trials · no comparable figure reported3 of 6 results reported a benefit2019 study 1 ↗2021 study 2 ↗
- Treatment response rateNo clear difference20% higher odds1 review of trials0 of 2 results reported a benefit2021 study ↗
Also measured in these studies (1)
These were measured alongside, but they are not what this condition is about.
- Quality of lifeNo clear differenceslight standardised effect1 review of trials2021 study ↗
Side effects: measured in 3 results. No result reported more side effects than the comparison group.
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every result is listed below.
See every resultThe connection
Major depression, persistent low mood and related conditions.
Also known as: Fish Oil, Krill Oil, EPA, DHA
Omega-3 (EPA/DHA) × Depression: at a glance
Every published result for this pair, extracted and audited.
These charts count reported findings from published studies, grouped by reported benefit and study design. Study design is not a certainty grade.
Omega-3 (EPA/DHA) / Depression: reported findings; one study may contribute several findings.
What the evidence shows
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| Benefit | 3 |
| No benefit | 10 |
Study designs behind these findings
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| Meta-analysis | 4 |
| Systematic review | 9 |
- Studies
- 2
| Study | Outcome | Reported result | Uncertainty (as reported) | Study duration |
|---|---|---|---|---|
| Efficacy of omega-3 PUFAs in depression: A meta-analysis. (PMID 31383846) | depression symptoms | -0.28 SMD | P=0.004 | Not reported |
| Efficacy of omega-3 PUFAs in depression: A meta-analysis. (PMID 31383846) | depression symptoms (DHA-pure and DHA-major) | Not reported | Not reported | Not reported |
| Efficacy of omega-3 PUFAs in depression: A meta-analysis. (PMID 31383846) | depression symptoms (EPA-major) | -1.03 SMD | P=0.03 | Not reported |
| Efficacy of omega-3 PUFAs in depression: A meta-analysis. (PMID 31383846) | depression symptoms (EPA-pure) | -0.50 SMD | P=0.003 | Not reported |
| Omega-3 fatty acids for depression in adults. (PMID 34817851) | adverse events | 1.27 OR | 95% CI 0.99 to 1.64 | Not reported |
| Omega-3 fatty acids for depression in adults. (PMID 34817851) | depressive symptomology (continuous) | -0.40 SMD | 95% CI -0.64 to -0.16 | Not reported |
| Omega-3 fatty acids for depression in adults. (PMID 34817851) | depressive symptomology (vs antidepressants) | -0.70 MD | 95% CI -5.88 to 4.48 | Not reported |
| Omega-3 fatty acids for depression in adults. (PMID 34817851) | quality of life | -0.38 SMD | 95% CI -0.82 to 0.06 | Not reported |
| Omega-3 fatty acids for depression in adults. (PMID 34817851) | remission rates | 1.13 OR | 95% CI 0.74 to 1.72 | Not reported |
| Omega-3 fatty acids for depression in adults. (PMID 34817851) | response rates | 1.20 OR | 95% CI 0.80 to 1.79 | Not reported |
| Omega-3 fatty acids for depression in adults. (PMID 34817851) | response rates (vs antidepressants) | 1.23 OR | 95% CI 0.35 to 4.31 | Not reported |
| Omega-3 fatty acids for depression in adults. (PMID 34817851) | trial non-completion | 0.92 OR | 95% CI 0.70 to 1.22 | Not reported |
| Omega-3 fatty acids for depression in adults. (PMID 34817851) | trial non-completion (vs antidepressants) | 1.00 OR | 95% CI 0.21 to 4.71 | Not reported |
Study results, as reported by the publications
Every measured outcome, one row per finding - numbers exactly as reported. Units are preserved where supplied; missing units are not inferred.
| Study and type | Reported sample and duration | Outcome measured | Reported result | What studies found |
|---|---|---|---|---|
| PMID 34817851 2021 Systematic review | Sample (as reported): 1503Duration: Not reported | adverse events | 1.27 OR (95% CI 0.99 to 1.64) | No benefit |
| PMID 34817851 2021 Systematic review | Sample (as reported): 1848Duration: Not reported | depressive symptomology (continuous) | -0.40 SMD (95% CI -0.64 to -0.16) | No benefit |
| PMID 34817851 2021 Systematic review | Sample (as reported): 40Duration: Not reported | depressive symptomology (vs antidepressants) | -0.70 MD (95% CI -5.88 to 4.48) | No benefit |
| PMID 34817851 2021 Systematic review | Sample (as reported): 476Duration: Not reported | quality of life | -0.38 SMD (95% CI -0.82 to 0.06) | No benefit |
| PMID 34817851 2021 Systematic review | Sample (as reported): 609Duration: Not reported | remission rates | 1.13 OR (95% CI 0.74 to 1.72) | No benefit |
| PMID 34817851 2021 Systematic review | Sample (as reported): 794Duration: Not reported | response rates | 1.20 OR (95% CI 0.80 to 1.79) | No benefit |
| PMID 34817851 2021 Systematic review | Sample (as reported): 40Duration: Not reported | response rates (vs antidepressants) | 1.23 OR (95% CI 0.35 to 4.31) | No benefit |
| PMID 34817851 2021 Systematic review | Sample (as reported): 1777Duration: Not reported | trial non-completion | 0.92 OR (95% CI 0.70 to 1.22) | No benefit |
| PMID 34817851 2021 Systematic review | Sample (as reported): 40Duration: Not reported | trial non-completion (vs antidepressants) | 1.00 OR (95% CI 0.21 to 4.71) | No benefit |
| PMID 31383846 2019 Meta-analysis | Sample (as reported): 2160Duration: Not reported | depression symptoms | -0.28 SMD (P=0.004) | Benefit |
| PMID 31383846 2019 Meta-analysis | Sample (as reported): Not reportedDuration: Not reported | depression symptoms (DHA-pure and DHA-major) | Not reported | No benefit |
| PMID 31383846 2019 Meta-analysis | Sample (as reported): Not reportedDuration: Not reported | depression symptoms (EPA-major) | -1.03 SMD (P=0.03) | Benefit |
| PMID 31383846 2019 Meta-analysis | Sample (as reported): Not reportedDuration: Not reported | depression symptoms (EPA-pure) | -0.50 SMD (P=0.003) | Benefit |
Omega-3 (EPA/DHA) × Depression: the evidence base
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Role of the EPA: DHA dosing ratio in omega-3 supplements on blood fatty acid profiles and inflammation: a systematic review and meta-analysisKhabir Z, et al. · Critical reviews in food science and nutrition · 2026PMID 41568426 ↗02Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled TrialsShafiee A, et al. · Nutrition reviews · 2025PMID 38913392 ↗03Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-AnalysisUrata M, et al. · Neuropsychopharmacology reports · 2025PMID 40014460 ↗04Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysisCheng YC, et al. · Psychological medicine · 2025PMID 40314175 ↗05Comparative Effectiveness of Nutritional Supplements in the Treatment of Knee Osteoarthritis: A Network Meta-AnalysisZhang Y, et al. · Nutrients · 2025PMID 40806131 ↗06A systematic review and dose response meta analysis of Omega 3 supplementation on cognitive functionShahinfar H, et al. · Scientific reports · 2025PMID 40836005 ↗Community experiences
Contributors volunteered; this does not establish treatment effectiveness or population incidence.
Reported changes
No publishable community breakdown is available. This does not establish that no reports exist.